Premium
Retrospective analysis of prognostic significance of the estrogen‐inducible pS2 gene in male breast carcinoma
Author(s) -
Kardaś Iwona,
Seitz Gerhard,
Limon Janusz,
Niezabitowski Aleksander,
Ryś Janusz,
Theisinger Birgit,
Welter Cornelius,
Blin Nikolaus
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930901)72:5<1652::aid-cncr2820720526>3.0.co;2-4
Subject(s) - medicine , estrogen , immunostaining , breast cancer , breast carcinoma , oncology , carcinoma , mammary gland , estrogen receptor , monoclonal antibody , pathology , cancer , immunohistochemistry , antibody , immunology
Background . The estrogen‐inducible pS2 gene, originally isolated from a breast cancer cell line, is correlated with hormone‐dependent female breast tumors and its expression is associated with longer overall and disease‐free survival. Methods . The authors have investigated 38 samples of carcinomas of the male breast for pS2 expression by using a monoclonal antibody. The immunostaining was compared with clinical data, in particular, to the progesterone receptor status, to assess a possible prognostic value of this parameter. Results . Although most cases (27 of 38) were immunopositive (i.e., above the 5th percentile of immunoreactive cells), no correlation with tumor grade and survival was notable. Conclusions . Therefore, on the contrary to the situation in female breast cancer, pS2 activity failed to constitute a new prognostic parameter in male breast carcinomas.